Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced preclinical data highlighting an ...
VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor more potent than other KRAS G12D inhibitors in preclinical models VS-7375, when combined with cetuximab, demonstrated strong tumor ...
BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the ...
SOUTH SAN FRANCISCO, Calif. and BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on ...
Co-primary efficacy in RAS G12–mutant PDAC included statistically significant OS and PFS gains assessed by blinded ...
Revolution Medicines shared Phase III clinical trial results for a pill called daraxonrasib in patients with previously ...
Hosted on MSN
Experimental drug findings pave way for clinical trial to target cancer's elusive growth switch
Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS and a key ...
Highlights: The study examines anti-RAS activity in a series of RAS inhibitors with a predicted unique interaction region. The compounds, in development at Qualigen Therapeutics, bind wild type KRAS ...
Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue [KRAS], neuroblastoma RAS viral oncogene homologue [NRAS], ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results